B17.0 Acute delta-(super) infection of hepatitis B carrier

Name of the Condition

• Acute delta-(super) infection of hepatitis B carrier

Summary

Acute delta-(super) infection of hepatitis B carrier describes a superinfection in individuals with chronic hepatitis B, where the hepatitis D virus (HDV) is acquired. This condition can lead to acute exacerbation of liver disease, potentially causing more severe symptoms and complications compared to chronic hepatitis B alone. The infection may resolve or progress to chronic delta hepatitis, depending on the host's immune response and viral factors.

Causes

Acute delta-(super) infection occurs when a person with chronic hepatitis B is infected with the hepatitis D virus (HDV). HDV is a defective virus that requires the presence of hepatitis B surface antigen (HBsAg) to replicate, making it dependent on hepatitis B virus (HBV) for its life cycle. Transmission routes include exposure to infected blood or bodily fluids, similar to HBV.

Risk Factors

• Chronic hepatitis B carrier status.
• Exposure to infected blood or bodily fluids (e.g., through needle sharing, unprotected sex, or medical procedures with contaminated equipment).
• Immunocompromised states that may alter the course of infection.
• Geographic regions with high HDV prevalence.

Symptoms

• Worsening of existing hepatitis B symptoms (e.g., fatigue, jaundice, abdominal pain).
• Acute hepatitis-like symptoms, including nausea, vomiting, and loss of appetite.
• Elevated liver enzymes (ALT/AST) indicating liver inflammation.
• In severe cases, signs of acute liver failure (e.g., encephalopathy, coagulopathy).

Diagnosis

Diagnosis involves confirming chronic hepatitis B (via HBsAg positivity) and detecting HDV infection. Laboratory tests include HDV antigen (HDAg) or antibody (anti-HDV) detection, HDV RNA testing for active infection, and liver function tests. Imaging or liver biopsy may be used to assess liver damage.

Treatment Options

• Supportive care to manage symptoms (e.g., rest, hydration, nutrition).
• Antiviral therapy targeting HDV, though options are limited; pegylated interferon-alpha may be considered in some cases.
• Monitoring for liver function deterioration and complications.
• Avoidance of alcohol and hepatotoxic medications.

Prognosis and Follow-Up

Prognosis varies; some patients may experience resolution of acute infection, while others may develop chronic delta hepatitis. Follow-up includes regular liver function testing, viral load monitoring, and assessment for cirrhosis or liver cancer. Long-term management focuses on preventing disease progression.

Complications

• Fulminant hepatitis (rare but severe).
• Chronic delta hepatitis, increasing risk of cirrhosis and liver failure.
• Increased likelihood of hepatocellular carcinoma compared to chronic hepatitis B alone.

Lifestyle & Prevention

• Vaccination against hepatitis B (prevents HDV superinfection by eliminating HBsAg).
• Avoidance of high-risk behaviors (e.g., unprotected sex, needle sharing).
• Safe medical practices (e.g., sterile equipment, blood screening).
• Abstinence from alcohol to reduce liver stress.

When to Seek Professional Help

Seek immediate medical attention if symptoms worsen (e.g., severe jaundice, confusion, abdominal swelling) or if there are signs of acute liver failure. Regular follow-up is recommended for chronic carriers to monitor for complications.

Tips for Medical Coders

Code B17.0 is used for acute delta-(super) infection in hepatitis B carriers. Documentation should specify the chronic hepatitis B status and acute HDV superinfection. Ensure clarity on the acute nature of the delta infection and its relationship to the pre-existing carrier state.